Reprocessing Validation Is a Question, Not a Checkbox

What a recent Class I catheter recall makes plain about device-specific cleaning and reprocessing validation.

Residual particulate is not an exotic failure mode. It is one of the recognized hazards reprocessing validation exists to rule out. When that validation is treated as a document to complete rather than a question to answer, the particulate ships with the device.

In early 2026, the FDA escalated a Medline recall of reprocessed electrophysiology and ultrasound catheters to its most serious recall type, citing small residual particulates capable of causing an inflammatory response, systemic infection, embolism, or thrombosis. The recall was first finalized in July 2025 and later expanded, and across seven recalls it spans more than 1,800 reprocessed catheters originally manufactured by several major OEMs, with the source of the residual material still under evaluation at the time of reporting.

This is not only a third-party reprocessor's problem. The same logic governs any OEM that runs a reusable or loaner device program, where a single physical device cycles through use, soiling, and reprocessing many times before it is retired. The detail worth sitting with in this case is that the contamination source was still being characterized after the recall. If a validation program had defined where particulate could originate and tested for it under worst-case conditions, the source would be characterized before release, not after a most-serious-category recall. What follows is what device-specific reprocessing validation actually has to demonstrate, using the public record of this event as the reference point.

What the recall tells you and what it doesn't

The public facts are narrow and specific. The named failure modes are tied to vascular and intracardiac catheter use, and the lot counts and timeline belong to this event. None of that generalizes cleanly to every reusable or single-use device category. What does generalize is the underlying question: did the reprocessing validation prove the device is clean enough, by the right measurement method, after the maximum number of cycles it is labeled for?

For reprocessed single-use devices, the FDA's position is explicit. A reprocessor must demonstrate through 510(k) validation data, including functional performance, that the device remains as safe and effective as the predicate after the maximum intended number of reprocessing cycles. That is a high bar, and it is a cumulative one. A device that is clean after one cycle is not the device the validation has to clear. The device the validation has to clear is the one at the end of its labeled cycle count, where debris and particulate have had every opportunity to accumulate.

Residual debris is a documented hazard, not an edge case

This event is not the first signal that reprocessing can leave material behind. The FDA has documented that inadequate reprocessing can retain blood, tissue, and biological debris, and has described work to develop methods to quantify particulate biological debris retained in reusable devices across multiple soiling and cleaning cycles.

The peer-reviewed literature shows how stark the gap can be. A blinded comparative study found significant residual organic material on 81 of 84 industry-reprocessed single-use vessel-sealing devices, versus 0 of 84 new devices, spanning carbon, nitrogen, oxygen, sulfur, sodium, and phosphorus, assessed by visual, microscopic, and chemical analysis. That study covered vessel-sealing devices, not catheters, so the residual quantities and types differ. The point it makes is general: reprocessing can leave material behind when the process and its validation are not adequate to the device geometry.

The deficiencies the FDA has already flagged

The reason checkbox validation fails is not mysterious. The FDA has stated that its review of manufacturer-supplied validation data found many studies used inadequate test conditions and inappropriate measurement methods, including failure to use clinically relevant test soils. Each of those is a place where a program can look complete on paper and prove nothing in practice.

Three decisions separate a defensible reprocessing validation from a paperwork exercise:

• Test soil selection. The soil has to represent the worst-case clinical challenge the device sees, not a soil chosen because it is easy to apply or easy to remove. A soil that does not mimic the actual bioburden and particulate load the device encounters cannot demonstrate that the cleaning process removes the real thing.
• Worst-case soiling and device features. Lumens, joints, hinges, and mating surfaces hold debris. Validation has to challenge the hardest-to-clean features, soiled to the worst case, not a representative average across an easy-to-reach surface.
• Recovery and measurement method. A cleaning result is only as good as the method used to recover and quantify what remains. The FDA's observation about inappropriate measurement methods is a direct warning that a clean reading can be an artifact of a weak recovery method rather than a clean device.

The FDA's 2015 final guidance establishes the framework for the scientific formulation and validation of reprocessing instructions, including premarket expectations. It is a recommendation framework, not a set of device-specific acceptance criteria. Manufacturers still have to derive worst-case parameters for their particular design. That derivation is the work. Skipping it is what checkbox means.

Standards have advanced, but gray areas remain

The cleaning and reprocessing validation toolkit has matured. Current standards include AAMI ST98:2022 for cleaning validation, AAMI TIR12:2020 for reprocessing design, and ISO 15883-5:2021 for test soils and methods. Gaps remain. For example, clear guidance on end-of-life assessment for reusable devices is not currently available in industry standards, leaving manufacturers to determine service-life limits for their own devices. Those gray areas are exactly where device-specific engineering judgment has to fill in what the standards leave open. A standard tells you the categories of evidence you need. It does not tell you the worst-case soiling location on your specific catheter lumen.

Reprocessing validation sits inside the manufacturer's quality system, where it is governed as process validation and design output under the FDA's Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference. The work-environment and contamination controls that keep a reprocessing line from reintroducing particulate are governed by ISO 13485:2016 Clause 6.4, work environment and contamination control, and specifically Clause 6.4.2, which requires documented arrangements to prevent contamination of the work environment, personnel, or product. The corrective action that should follow any out-of-spec cleaning result flows through Clause 8.5.2, corrective action, which requires the organization to document a procedure for eliminating the root cause of detected nonconformities and preventing their recurrence. A validation that lives only as a binder, disconnected from those controls, is the failure pattern the QMSR framework is meant to close.

You cannot wait for the FDA to catch it

There is a reason upstream rigor matters more, not less, right now. A December 2025 GAO report found that the FDA lacks sufficient staff for device recall activities, with officials prioritizing the highest-risk recalls and deferring recall termination due to limited resources. That describes regulator capacity, not manufacturer obligation. But the implication for a reusable or loaner device program is direct: post-market detection is a thin safety net. The validation done before release is where the failure mode gets caught, or it does not.

A loaner or reusable device program multiplies the stakes, because the same physical device cycles through use, soiling, and reprocessing many times. Every cycle is an opportunity for debris to accumulate and for a process that passed at cycle one to fail by cycle fifty. Validation that does not test to the maximum labeled cycle count is testing a device that does not exist in the field.

What a defensible program proves

This recall is a public reminder of what reprocessing validation is for. A program built to prevent this class of failure proves, with device-specific evidence, that the cleaning process removes a clinically relevant worst-case soil from the hardest-to-clean features of the device, measured by a recovery method validated to detect what is actually there, after the maximum number of cycles the device is labeled to endure. Anything short of that is a document, not a defense.

LSO's cleaning and decontamination and sterilization validation services are built around that worst-case, device-specific logic rather than a generic protocol applied to every device. The difference is whether your validation answers the question an auditor and a patient are both asking: is this device actually clean, every cycle, to the end of its labeled life?